

This article was downloaded by:

On: 28 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713618290>

SYNTHESIS OF PHOSPHOLIPID CONJUGATES OF N¹-(2-FURANIDYL)-N³-(2-HYDROXYETHYL)-5-FLUOROURACIL

Huanming Chen^a; Ruyu Chen^a; Pingying Li^b

^a Institute of Elemento-Organic Chemistry, The State Key Laboratory of Elemento-Organic Chemistry, Nankai University, Tianjin, China ^b Institute of Polymer Chemistry, Nankai University, Tianjin, China

To cite this Article Chen, Huanming , Chen, Ruyu and Li, Pingying(1997) 'SYNTHESIS OF PHOSPHOLIPID CONJUGATES OF N¹-(2-FURANIDYL)-N³-(2-HYDROXYETHYL)-5-FLUOROURACIL', Phosphorus, Sulfur, and Silicon and the Related Elements, 122: 1, 1 – 7

To link to this Article: DOI: 10.1080/10426509708043490

URL: <http://dx.doi.org/10.1080/10426509708043490>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS OF PHOSPHOLIPID CONJUGATES OF N¹-(2-FURANIDYL)-N³-(2-HYDROXYETHYL)-5-FLUOROURACIL

HUANMING CHEN^a, RUYU CHEN^{a,*} and PINGYING LI^b

^a*Institute of Elemento-Organic Chemistry, The State Key Laboratory of Elemento-Organic Chemistry, Nankai University, Tianjin 300071, China;* ^b*Institute of Polymer Chemistry, Nankai University, Tianjin 300071, China*

(Received 7 February 1995; Revised 29 March 1996; In final form 29 March 1996)

The synthesis of phospholipid conjugates of N¹-(2-furanidyl)-N³-(2-hydroxyethyl)-5-fluorouracil is reported. The strategy for the synthesis is using hexaethylphosphorous triamide, activated by a catalytic amount of iodine, as the phosphorylating reagent in a one-pot reaction resulting in a number of new types of phospholipid-drug conjugates.

Keywords: Phospholipids; glyceramidothiophosphates; conjugates; 5-fluorouracil derivatives; hexaethylphosphorous triamide

INTRODUCTION

Phospholipid-nucleoside conjugates have demonstrated potent antitumor activity *in vitro* and *in vivo*^{1,2,3}. The conjugates are not only prodrugs or molecular depots of nucleoside antitumor agents but also may generate two cytotoxic groups with different target sites, membrane and synthesis of nucleic acid, inside a neoplastic cell⁴. These interesting biological activities lead us to synthesize new types of phospholipid conjugates of 5-fluorouracil derivatives. Various types of 5-fluorouracil derivatives have been widely used as effective chemotherapeutics against neoplastic cells. For example, 1,3-bis(hydroxyalkyl)-5-fluorouracil have been described as antitumor compounds⁵, and N¹-(2-furanidyl)-5-fluorouracil (Tegafur) is a potent inhibitor of mammalian cell growth in clinical use. However, their side effects, such as hot sensation and

*Corresponding author.


pollakiuria syndrome, encourage people to develop a better new drug.⁶ So is our aim to synthesize highly biologically active and less toxic new phospholipid conjugates of 5-fluorouracil derivatives.

RESULTS AND DISCUSSION


Tegafur (**1**) is one of the 5-fluorouracil antitumor agents. In order to improve its antitumor activity, we attempted to synthesize its conjugates of glycerophospholipids. According to Scheme 1, the alkylation of tegafur (**1**) with bromoethanol was carried out in acetonitrile in the presence of triethylamine at room temperature for 48 hours, and the yield was only 78% due to less active N³ position of the uracil ring⁷.

Scheme 2 described the synthesis of (rac-1-O-octadecyl-2-O-acetylglyceryl-3-O)-[1-(N¹-(2-furanidyl)-5-fluorouracil-N³-)ethyl-2-O-](N,N-diethylamido)thiophosphate (**8**). The primary hydroxyl group of **3** was converted to the corresponding trityl ether **4** by allowing **3** to react with triphenylmethyl chloride in anhydrous pyridine in excellent yield as reported earlier⁸ with some modifications of solvent and purification. Acid-catalyzed cleavage of the trityl ether **5** obtained from the acetylation of **4** in 80% acetic acid at 60°C yielded the alcohol **6** as a waxy product⁹ in 52% yield after isolation by column chromatography.

Compound **8** was obtained in 55% yield by a one-pot (two-step) reaction from rac-1-O-octadecyl-2-O-acetylglycerol (**6**) by means of hexaethylphosphorous triamide, activated by iodine, as a phosphorylating reagent under mild conditions according to the procedure of Stamalov¹⁰. Thus, the activated phosphoramidite was reacted with the alcohol **6** in stoichiometric amounts at 65°C to give the bis(N,N-diethylamido)-phosphite (**7**) in nearly quantitative yield. The consecutive treatment of the intermediate (**7**) with an equivalent amounts of the



SCHEME 1




SCHEME 2

hydroxyethyltegafur (2) and sulfur at 65°C for 5 hr. and 30 min respectively afforded glyceramidothiophosphate (8), which was isolated by column chromatography.

According to Scheme 3, (rac-1,3-O-distearoylglycerol-2-O)-[1-(N¹-(2-furanidyl)-5-fluorouracil)-N³-ethyl-2-O]-[N,N-diethylamido)-thiophosphate (10) was synthesized from rac-1,3-O-distearoylglycerol (9)¹¹ and N¹-(2-furanidyl)-N³-(2-hydroxyethyl)-5-fluorouracil (2) by using the same procedure as for preparation of 8. The yield was only 42% because of severe steric hindrance of the free hydroxy group in 9.

Physicochemical properties and biological activities of glyceramidothiophosphates 8 and 10 are under investigation. These results will be discussed in detail in another paper.



SCHEME 3

EXPERIMENTAL

IR spectra were recorded on NICOLET 5DX instrument. NMR spectra were taken on a BRUKER AC-P200 spectrometer, TMS as an internal standard for ^1H NMR and 85% H_3PO_4 as an external standard for ^{31}P NMR. Elemental analyses were carried out with a YANACO CHN CORDER MT-3 elementary analyser. Melting points were uncorrected.

Benzene and pyridine were distilled from sodium and potassium hydroxide respectively before being used. Petroleum ether refers to a fraction bp 60–90°C. Column chromatography was carried out with silica gel H (10–40 μm).

Hexaethylphosphorous triamide was prepared according to literature¹² and freshly distilled.

N^1 -(2-Furanidyl)- N^3 -(2-Hydroxyethyl)-5-Fluorouracil (2)

A solution of 10.0g(0.05 mol) of N^1 -(2-furanidyl)-5-fluorouracil (1), 7.5g (0.06 mol) of 2-bromoethanol and 6.1g(0.06 mol) of triethylamine in 100 ml of acetonitrile was stirred for 48h at r.t. The solvent was evaporated and the residue was extracted with ethyl acetate. The extract was dried (MgSO_4) and concentrated *in vacuo* to give a crude product, which was recrystallized from benzene to afford white crystals (9.5g, 78%). m.p. 88–90°C; $\text{C}_{10}\text{H}_{13}\text{FN}_2\text{O}_4$. Calcd: C, 49.18; H, 5.37; N, 11.47, Found: C, 49.32, H, 5.20; N, 11.58. ^1H NMR(CDCl_3) δ 1.79–2.46(4H, m, 3',4'- CH_2), 3.84(2H, t, $J = 4.9\text{Hz}$, NCH_2), 3.99(1H, m, 5'-Ha), 4.19(2H, t, $J = 4.9\text{Hz}$, HOCH_2), 4.20(1H, m, 5'-Hb), 5.96(1H, brd, 2'-H), 7.40(1H, d, $J_{\text{H-F}} = 5.4\text{Hz}$, 6-H).

Rac-1-O-Octadecyl-3-O-Tritylglycerol (4)

The compound was prepared according to a literature procedure⁸ with modifications. A solution of 17.2g(0.05 mol) of rac-1-O-octadecylglycerol (3) and 17.0g(0.06 mol) of trityl chloride in 100ml of anhydrous pyridine was stirred at 70°C for 24h. The solvent was evaporated *in vacuo*, and the residue was dissolved in 200 ml of diethyl ether. The ether layer was washed with 5% hydrochloric acid and water, and dried over MgSO_4 . The solvent was evaporated, and the oily residue was dissolved in 100 ml of dichloromethane. After cooling at -15°C overnight, the precipitated tritylalcohol was filtered off, and the filtrate was evaporated. The crude product remained was recrystallized from petroleum ether to yield a white solid (28.1g, 96%). TLC: $R_f = 0.31$ (petroleum ether/ethyl acetate, 20:1, v/v). m.p. 58–59°C (lit.¹³ m.p. 59.5–60.5°C); ^1H NMR(CDCl_3) δ

0.86(3H, t, CH₃), 1.24(30H, brs, (CH₂)₁₅), 1.54(2H, quintet, OCH₂CH₂(CH₂)₁₅CH₃), 3.18(2H, d, J = 6.3Hz, CH₂OTr), 3.37–3.54(4H, m, CH₂OCH₂), 3.93(1H, quintet, CH), 7.24–7.44(15H, m, (C₆H₅)₃).

Rac-1-O-Octadecyl-2-O-Acetyl-3-Tritylglycerol (5)

A mixture of 5.9g(0.01 mol) of rac-1-O-octadecyl-3-O-tritylglycerol (4), 20 ml of anhydrous pyridine and 6 ml of acetic anhydride was stirred at r.t. for 40 h. Then, 50 ml of water was added, and the mixture was extracted with chloroform. The organic layer was washed with 5% hydrochloric acid and water, dried with MgSO₄, and evaporated *in vacuo*. The residue was recrystallized from petroleum ether to give white solid (6.3g, ~ 100%) R_f value: 0.66(petroleum ether/ethyl acetate, 20:1, v/v) m.p. 49–50 °C; C₄₂H₆₀O₄ Calcd: C, 80.21; H, 9.62; Found: C, 80.34; H, 9.55. ¹H NMR(CDCl₃) δ 0.86(3H, t, CH₃), 1.24(30H, brs, (CH₂)₁₅), 1.54(2H, quintet, OCH₂CH₂(CH₂)₁₅CH₃), 2.08(3H, s, COCH₃), 3.20–3.80(6H, m, CH₂CHCH₂OCH₂), 5.17(1H, quintet, CH), 7.24–7.44(15H, m, (C₆H₅)₃).

Rac-1-O-Octadecyl-2-O-Acetyl-glycerol (6)^{9,13}

Compound (6) was prepared by a literature procedure¹⁴ from 5: yield 52%; R_f value: 0.23(petroleum ether/ethyl acetate, 20:1 v/v) m.p. 45–46 °C(lit.¹³ m.p. 47 °C).

(rac-1-O-Octadecyl-2-O-Acetyl-glycerol-3-O)-[1-(N¹-(2-Furanidyl)-5-Fluorouracil-N³-) Ethyl-2-O-](N,N-Diethylamido)-Thiophosphate (8)

A mixture of 0.39g (1 mmol) of rac-1-O-octadecyl-2-O-acetyl-glycerol (6), 0.26g (1.05 mmol) of hexaethylphosphorous triamide and 0.013 g (0.05 mmol) of iodine in 25 ml of anhydrous benzene was stirred at 65 °C for about 30 min until the solution became clear. 0.24g(1 mmol) of N¹-(2-furanidyl)-N³-(2-hydroxyethyl)-5-fluorouracil (2) was then added, and the mixture was continuously stirred at 65 °C for 5h. Then 0.033 g(1.05 mmol) of sulfur was added and the reaction system was kept under the same conditions for 30 min. The solvent was evaporated *in vacuo*, and the residue was chromatographed by silica gel column using petroleum ether—ethyl acetate (5:1) as the eluent. A colourless oily product (0.42g, 55.1%) was obtained. R_f value: 0.59(petroleum ether/ethyl acetate, 5:1 v/v). C₃₇H₆₇FN₃O₈PS. Calcd: C, 58.17; H, 8.84; N, 5.50. Found: C, 58.23; H, 8.66; N, 5.41. IR ν_{max}(liq) 1742, 1715, 1677, 1660, 1464, 1263, 1220, 1076, 1023, 790, 754, 718 cm⁻¹; ¹H NMR(CDCl₃) δ 0.83(3H, t, J = 6.0Hz,

CH₃), 1.02(6H, t, J = 6.9Hz, N(CH₂CH₃)₂), 1.21(30H, brs, (CH₂)₁₅), 1.51(2H, m, OCH₂CH₂), 2.01(3H, s, COCH₃), 1.79–2.46(4H, m, 3',4'-CH₂), 3.12(4H, m, N(CH₂CH₃)₂), 3.37–3.64(6H, m, CH₂CHCH₂OCH₂), 3.98(1H, m, 5'-Ha), 4.02–4.33(5H, m, 5'-Hb, OCH₂CH₂N), 4.57(1H, quintet, CH), 5.92(1H, brs, 2'-H), 7.34(1H, d, J_{H-F} = 5.4Hz, 6-H); ³¹P NMR(CDCl₃) δ 77.63, 77.52, 76.99.

(Rac-1,3-O-Distearoylglyceryl-2-O)-[1-(N¹-(2-Fluranidyl)-5-Fuorouracil-N³-) Ethyl-2-O-](N,N-Diethylamido)-Thiophosphate (10)

The glyceramidothiophosphate **10** was synthesized and purified by using rac-1,3-O-distearoylglycerol **11** (9, 0.624g, 1.0 mmol) and N¹-(2-furanidyl)-N³-(2-hydroxyethyl)-5-fluorouracil (2, 0.244g, 1.0 mmol) in the same way as described for compound **8**. The product was recrystallized from methanol to give white crystals (0.42g, 42%). R_f value: 0.79 (petroleum ether/ethyl acetate, 5:1, v/v). m.p. 44–46 °C. C₅₃H₉₇FN₃O₉PS Calcd: C, 63.51; H, 9.75; N, 4.19. Found: C, 63.64; H, 9.51; N, 3.99. IR ν_{max}(KBr) 1733, 1652, 1463, 1259, 1160, 1068, 1020, 786, 752, 716 cm⁻¹. ¹H NMR(CDCl₃) δ 0.85(3H, t, J = 6.0Hz, CH₃), 1.03(6H, t, J = 6.8Hz, N(CH₂CH₃)₂), 1.23(56H, brs, 2 × (CH₂)₁₄), 1.58(4H, m, 2 × COCH₂CH₂), 2.29(4H, m, 2 × COCH₂), 1.83–2.45(4H, m, 3',4'-CH₂), 3.14(4H, m, N(CH₂CH₃)₂), 3.86–4.39(10H, m, CH₂CHCH₂, 5'-CH₂, OCH₂CH₂N), 4.68(1H, quintet, CH), 5.96(1H, brs, 2'-H), 7.36(1H, d, J_{H-F} = 5.5Hz, 6-H). ³¹P NMR(CDCl₃) δ 77.78, 77.67.

Acknowledgement

This project is supported by National Natural Science Foundation of China.

References

- [1] E. K. Ryu, R. J. Ross, T. Matsushita, M. MacCoss, C. I. Hong and C. R. West, *J. Med. Chem.*, **25**, 1322, (1982).
- [2] S. Shuto, H. Itoh, K. Fukukawa and M. Tsujino, *U.S. Pat.* 5051499(1991); 4921951, (1990).
- [3] T. Matsushita, E. K. Ryu, C. I. Hong, M. MacCoss, *Cancer Res.*, **41**, 2707, (1981).
- [4] C. I. Hong, A. J. Kirisits, A. Nechaev, D. J. Buchheit and C. R. West, *J. Med. Chem.*, **33**, 1380, (1990).
- [5] F. Changlie, M. Caisong, Y. Hui, X. Jianing, D. Qizhu and Z. Renxi, *Wuhan Daxue Xuebao Ziran Kexueban*, **115**, (1984) [*Chem. Abstr.*, **102**, 6404f, (1985)].
- [6] M. Yasumoto, I. Yamawaki, T. Marunaka, S. Hashimoto, *J. Med. Chem.*, **21**, 738, (1978).
- [7] T. Nagase, K. Seike, K. Shiraishi, Y. Yamada, and S. Ozaki, *Chem. Lett.*, 1381, (1988).
- [8] C. I. Hong, S. An, D. J. Buchheit, A. Nechaev, A. J. Kirisits, C. R. West, and W. E. Berdel, *J. Med. Chem.*, **29**, 2038, (1986).
- [9] J. J. Godfroid, C. Broquet, S. Jouquey, M. Lebbar, F. Heymans, C. Redeuilh, E. Steiner, E. Michael, E. Coeffier, J. Fichelle, M. Worcel, *J. Med. Chem.*, **30**, 792, (1987).
- [10] S. D. Stamatov and S. A. Ivanov, *Phosphorus Sulfur*, **40**, 167, (1988).

- [11] W. G. Rose, *J. Am. Chem. Soc.*, **69**, 1384, (1947).
- [12] A. B. Burg and P. J. Slota, *J. Am. Chem. Soc.*, **80**, 1107, (1958).
- [13] G. Hirth and R. Barner, *Helv. Chim. Acta*, **65**, 1059, (1982).
- [14] K. L. Meyer, S. W. Schwendner, R. E. Counsell, *J. Med. Chem.*, **32**, 2142, (1989).